eNauka - pregled

Pregled prema Autor Panzara, Michael

Prikaz rezultata 1 do 4 od 4
GodinaNaslovAutor(i)Tip rezultataMp-kat.
2012Effect of Alemtuzumab vs. Rebif (R) on Brain MRI Measurements: Results of CARE-MS I, a Phase 3 StudyArnold, Douglas L; Brinar, Vesna; Cohen, Jeffrey; Coles, Alasdair; Confavreux, Christian; Fisher, Elizabeth; Fox, Edward; Giovannoni, Gavin; Hartung, Hans; Havrdova, Eva;
Selmaj, Krzysztof; Weiner, Howard; Stojanovic, Miroslav; Lake, Stephen; Margolin, David; Panzara, Michael; Compston, Alastair;
Konferencijski rad
Mp kategorija će biti prikazana naknadno.
2012Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naive PatientsColes, Alasdair; Brinar, Vesna; Arnold, Douglas L; Cohen, Jeffrey; Confavreux, Christian; Fox, Edward; Hartung, Hans; Havrdova, Eva; Selmaj, Krzysztof; Weiner, Howard;
Giovannoni, Gavin; Stojanovic, Miroslav; Lake, Stephen; Margolin, David; Panzara, Michael; Compston, Alastair;
Konferencijski rad
Mp kategorija će biti prikazana naknadno.
2012Infections in Phase 3 Study: Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis I (CARE-MS I)Havrdova, Eva; Arnold, Douglas L; Cohen, Jeffrey; Coles, Alasdair; Confavreux, Christian; Fox, Edward; Hartung, Hans; Selmaj, Krzysztof; Weiner, Howard; Brinar, Vesna;
Giovannoni, Gavin; Stojanovic, Miroslav; Lake, Stephen; Margolin, David; Oyuela, Pedro; Panzara, Michael; Compston, Alastair;
Konferencijski rad
Mp kategorija će biti prikazana naknadno.
2012Relapse Outcomes with Alemtuzumab vs. Rebif (R) in Treatment-Naive Relapsing-Remitting Multiple Sclerosis (CARE-MS I): Secondary and Tertiary EndpointsFox, Edward; Arnold, Douglas L; Brinar, Vesna; Cohen, Jeffrey; Coles, Alasdair; Confavreux, Christian; Giovannoni, Gavin; Hartung, Hans; Havrdova, Eva; Selmaj, Krzysztof;
Stojanovic, Miroslav; Weiner, Howard; Lake, Stephen; Margolin, David; Panzara, Michael; Compston, Alastair;
Konferencijski rad
Mp kategorija će biti prikazana naknadno.